Orchestra BioMed Holdings Inc. (NASDAQ: OBIO) announced it is targeting completion of enrollment for its BACKBEAT Global Pivotal Trial by ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA